7月28日，葛兰素史克盘中上涨4.44%，报54.67美元/股，成交额4353.41万美元。
消息面上，公司当日公布二季度财报，调整后每股收益1.35美元，超出市场预期的1.27美元，同比增长8.87%；营收112.8亿美元，高于预期的107.9亿美元。公司同时宣布目标在2029年前全面实现每年19亿英镑的成本节约，并表示现有营收与收益流规模足以抵消艾滋病药物专利失效带来的损失。此外，公司近期完成106亿美元收购Nuvalent，加码肿瘤管线布局，肺癌新药Jideytro获FDA批准，多重积极因素共同推动股价走强。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.